Improving Outcomes for Early Onset Breast Cancer

For patients diagnosed with early-onset breast cancer getting such a diagnosis can be scary and seem devastating. However, with a team effort by patients and their doctors, there are treatment options that can help treat patients at various ages of diagnosis. 

Nearly 11% of breast cancer patients are under 45, and because of their young age, the condition is not found until later stages, which can make it harder to treat. Physicians should be aware of several modifiable risk factors, including weight gain after age 18, physical inactivity, and alcohol consumption. According to the video, there are steps that can be taken to help address these risk factors, including maintaining a healthy weight, exercising regularly, and either eliminating alcohol consumption or limiting it to one drink per day.  

There are also some non-modifiable risk factors as well, including a family history of early-onset breast cancer or ovarian cancer, Ashkenazi Jewish patients, people with a family history of genetic mutations like BRCA, or a history of chest radiation treatment. While these risk factors cannot be modified, they can be addressed by doctors, or, in some cases genetic counselors. 

Doctors should also remind patients that just because they have these risk factors, it does not mean they will develop breast cancer. 

By Adam Hochron

Video Source: Youtube.com

Video Credit: Centers for Disease Control and Prevention (CDC)

Next Up In Breast Cancer

NCCN Clinical Practice Guidelines Recommend FES PET Imaging for ER+ Breast Cancer 2:10 MD /Alert Exclusive

NCCN Clinical Practice Guidelines Recommend FES PET Imaging for ER+ Breast Cancer

Less Frequent Mammography for Breast Cancer Survivors Has No Impact on Survival 2:42 MD /Alert Exclusive

Less Frequent Mammography for Breast Cancer Survivors Has No Impact on Survival

Greater Weight Loss Among Women with Breast Cancer After Phone-Based Coaching 2:35 LIVE FROM ASCO

Greater Weight Loss Among Women with Breast Cancer After Phone-Based Coaching

Donepezil Does Not Improve Cancer-Related Cognitive Impairment in Breast Cancer Survivors 2:26 LIVE FROM ASCO

Donepezil Does Not Improve Cancer-Related Cognitive Impairment in Breast Cancer Survivors

Younger Postmenopausal Patients May Skip Adjuvant Radiotherapy After Early Breast Cancer Surgery 2:50 MD /Alert Exclusive

Younger Postmenopausal Patients May Skip Adjuvant Radiotherapy After Early Breast Cancer Surgery

Tucatinib Plus Trastuzumab Emtansine Extend PFS in Late-Stage HER2-Positive Breast Cancer 2:42 MD /Alert Exclusive

Tucatinib Plus Trastuzumab Emtansine Extend PFS in Late-Stage HER2-Positive Breast Cancer

Capecitabine Has Less Toxicity, Similar Survival in Metastatic Breast Cancer with Fixed Dose 2:07 LIVE FROM ASCO

Capecitabine Has Less Toxicity, Similar Survival in Metastatic Breast Cancer with Fixed Dose

Patients with Breast Cancer That Converts from Lymph Node-Positive to -Negative Can Skip Adjuvant Irradiation 2:30 MD /Alert Exclusive

Patients with Breast Cancer That Converts from Lymph Node-Positive to -Negative Can Skip Adjuvant Irradiation

Pertuzumab, Trastuzumab Combination Effective in HER2+ Metastatic Breast Cancer 3:20 MD /Alert Exclusive

Pertuzumab, Trastuzumab Combination Effective in HER2+ Metastatic Breast Cancer

PET-CT Scanning Improves Detection of Metastases in Patients With Locally Advanced Breast Cancer 3:21 MD /Alert Exclusive

PET-CT Scanning Improves Detection of Metastases in Patients With Locally Advanced Breast Cancer

Sacituzumab Govitecan Improves OS in Endocrine-Resistant Metastatic Breast Cancer 2:50 MD /Alert Exclusive

Sacituzumab Govitecan Improves OS in Endocrine-Resistant Metastatic Breast Cancer

ASCO, SSO Publish Guidelines for Germline Mutation Testing in Breast Cancer MD /Alert Exclusive

ASCO, SSO Publish Guidelines for Germline Mutation Testing in Breast Cancer

HER3-DXd Promotes Clinical Activity in MBC at Varying HER3 Expression Levels 3:50 LIVE FROM ASCO

HER3-DXd Promotes Clinical Activity in MBC at Varying HER3 Expression Levels

Breast Cancer Index Risk Scores a Prognostic Indicator of Overall, Late Distant Recurrence 2:20 LIVE FROM ASCO

Breast Cancer Index Risk Scores a Prognostic Indicator of Overall, Late Distant Recurrence

Fertility Preservation Safe for Patients Who Pause HR-positive Breast Cancer Endocrine Therapy to Conceive 2:46 MD /Alert Exclusive

Fertility Preservation Safe for Patients Who Pause HR-positive Breast Cancer Endocrine Therapy to Conceive

FDA Approves Biosimilar Treatment for Cancer-Related Neutropenia 1:03 MD /Alert Exclusive

FDA Approves Biosimilar Treatment for Cancer-Related Neutropenia

FDA Gives Priority Review for HR+, HER2– Advanced Breast Cancer Therapy 1:45 MD /Alert Exclusive

FDA Gives Priority Review for HR+, HER2– Advanced Breast Cancer Therapy

20-Year Benefit from Endocrine Therapy in Premenopausal Patients with Breast Cancer 2:43 MD /Alert Exclusive

20-Year Benefit from Endocrine Therapy in Premenopausal Patients with Breast Cancer

Lumpectomy, Mastectomy Result in Similar Outcomes in Younger Patients with Breast Cancer 2:22 MD /Alert Exclusive

Lumpectomy, Mastectomy Result in Similar Outcomes in Younger Patients with Breast Cancer

Treatment Combination Shows Promise in HR+, HER2–, HER2-mutant Metastatic Breast Cancer 3:18 MD /Alert Exclusive

Treatment Combination Shows Promise in HR+, HER2–, HER2-mutant Metastatic Breast Cancer

FDA Committee Delays Approval of Pembrolizumab for Early TNBC 2:25 MD /Alert Exclusive

FDA Committee Delays Approval of Pembrolizumab for Early TNBC

Ribociclib, Endocrine Therapy Combination Improves PFS in Aggressive Breast Cancer 3:16 MD /Alert Exclusive

Ribociclib, Endocrine Therapy Combination Improves PFS in Aggressive Breast Cancer

Mindfulness Shows Benefits for Young Breast Cancer 4:40 MD /Alert Exclusive

Mindfulness Shows Benefits for Young Breast Cancer

FDA Accepts Biologics License Application for New Metastatic HER2+ Breast Cancer Treatment 2:06 MD /Alert Exclusive

FDA Accepts Biologics License Application for New Metastatic HER2+ Breast Cancer Treatment

Advanced ER+ HER2+ Breast Cancer Combo Therapy Fails to Improve Outcomes 3:30 MD /Alert Exclusive

Advanced ER+ HER2+ Breast Cancer Combo Therapy Fails to Improve Outcomes

European Commission Approves Trastuzumab Deruxtecan for Second-Line HER2+ Breast Cancer 1:53 MD /Alert Exclusive

European Commission Approves Trastuzumab Deruxtecan for Second-Line HER2+ Breast Cancer

Zanidatamab-Docetaxel Effective as First-Line Therapy in Advanced HER2+ Breast Cancer 3:28 MD /Alert Exclusive

Zanidatamab-Docetaxel Effective as First-Line Therapy in Advanced HER2+ Breast Cancer

Pertuzumab-Based Regimen Continues to Reduce Recurrence in Patients with Early Breast Cancer 2:44 MD /Alert Exclusive

Pertuzumab-Based Regimen Continues to Reduce Recurrence in Patients with Early Breast Cancer

Neoadjuvant Opportunities in Early, High-Risk Breast Cancer 5:58 Medscape

Neoadjuvant Opportunities in Early, High-Risk Breast Cancer

Study Shows Tolerable Safety of Abemaciclib Plus Pembrolizumab in HER2-, Metastatic Breast Cancer 2:21 MD /Alert Exclusive

Study Shows Tolerable Safety of Abemaciclib Plus Pembrolizumab in HER2-, Metastatic Breast Cancer

Combining Eribulin and Pembrolizumab in Metastatic Triple-Negative Breast Cancer 3:09 MD /Alert Exclusive

Combining Eribulin and Pembrolizumab in Metastatic Triple-Negative Breast Cancer

New Test May Detect Multiple Cancers, Tumor Points of Origin 3:02 MD /Alert Exclusive

New Test May Detect Multiple Cancers, Tumor Points of Origin

FDA Approves Combo of Abemaciclib, Endocrine Therapy for Early Breast Cancer 1:51 MD /Alert Exclusive

FDA Approves Combo of Abemaciclib, Endocrine Therapy for Early Breast Cancer

Camizestrant Improves PFS in Patients with HR+/HER2– Breast Cancer 3:56 MD /Alert Exclusive

Camizestrant Improves PFS in Patients with HR+/HER2– Breast Cancer

Protein Coding Gene Enhances Cisplatin Resistance in Triple-Negative Breast Cancer 2:45 MD /Alert Exclusive

Protein Coding Gene Enhances Cisplatin Resistance in Triple-Negative Breast Cancer

ICI-Related Major Adverse Cardiac Events Rare, but Cause Significant Morbidity 3:38 MD /Alert Exclusive

ICI-Related Major Adverse Cardiac Events Rare, but Cause Significant Morbidity

Improving Outcomes for Early Onset Breast Cancer 12:17 CDC

Improving Outcomes for Early Onset Breast Cancer

Study Shows Breastfeeding Can be Safe for Breast Cancer Survivors 4:08 MD /Alert Exclusive

Study Shows Breastfeeding Can be Safe for Breast Cancer Survivors

Olaparib Improves Survival in High Risk Early-Stage Breast Cancer 1:44 MD /Alert Exclusive

Olaparib Improves Survival in High Risk Early-Stage Breast Cancer

Inflammatory Markers May Predict Frailty After Chemotherapy 3:09 MD /Alert Exclusive

Inflammatory Markers May Predict Frailty After Chemotherapy

Results from BEATRICE and I–SPY2 Trials in TNBC and HR+/HER2- Breast Cancer 2:14 MD /Alert Exclusive

Results from BEATRICE and I–SPY2 Trials in TNBC and HR+/HER2- Breast Cancer

Metastatic Breast Cancer: 'The Journey Begins' 5:31 Medscape

Metastatic Breast Cancer: "The Journey Begins"

Neoadjuvant Amcenestrant Shows Robust Response in Postmenopausal ER+/HER2- Breast Cancer 2:29 MD /Alert Exclusive

Neoadjuvant Amcenestrant Shows Robust Response in Postmenopausal ER+/HER2- Breast Cancer

Time to Treatment Completion Associated with Poor Breast Cancer Survival 3:18 MD /Alert Exclusive

Time to Treatment Completion Associated with Poor Breast Cancer Survival

Nitric Oxide Synthase Inhibitor Plus Taxane Show Promise in Chemoresistant TNBC 4:30 MD /Alert Exclusive

Nitric Oxide Synthase Inhibitor Plus Taxane Show Promise in Chemoresistant TNBC

Trastuzumab Deruxtecan Highly Effective in Patients with HER2-Low Metastatic Breast Cancer 2:53 MD /Alert Exclusive

Trastuzumab Deruxtecan Highly Effective in Patients with HER2-Low Metastatic Breast Cancer

Large Epidemiology Study Updates Breast Cancer Risk for Women Lacking Family History 1:51 MD /Alert Exclusive

Large Epidemiology Study Updates Breast Cancer Risk for Women Lacking Family History

No Benefit with Early Local Therapy In De Novo Metastatic Breast Cancer 2:34 MD /Alert Exclusive

No Benefit with Early Local Therapy In De Novo Metastatic Breast Cancer

Therapy Targeting Inducible Nitric Oxide Signaling Shows Promise in TNBC 4:37 MD /Alert Exclusive

Therapy Targeting Inducible Nitric Oxide Signaling Shows Promise in TNBC

Metastatic Breast Cancer Therapy Gains Fast Track Designation 1:25 MD /Alert Exclusive

Metastatic Breast Cancer Therapy Gains Fast Track Designation

Trastuzumab Deruxtecan Significantly Improves OS, PFS in Patients with MBC 2:39 MD /Alert Exclusive

Trastuzumab Deruxtecan Significantly Improves OS, PFS in Patients with MBC

Study of Immunotherapy Combinations for Patients with Metastatic Breast Cancer 4:26 Dana Farber

Study of Immunotherapy Combinations for Patients with Metastatic Breast Cancer

Palbociclib Combination Fails to Extend Overall Survival for Advanced Breast Cancer 2:35 MD /Alert Exclusive

Palbociclib Combination Fails to Extend Overall Survival for Advanced Breast Cancer

NCCN Report Advises on Use of Pembrolizumab in Triple-Negative Breast Cancer 2:48 MD /Alert Exclusive

NCCN Report Advises on Use of Pembrolizumab in Triple-Negative Breast Cancer

Helping Breast Cancer Oncologists Work ‘In the Trenches’ 4:43 MD /Alert Exclusive

Helping Breast Cancer Oncologists Work ‘In the Trenches’

EU approves HER2+ Metastatic Breast Cancer Treatment 2:31 MD /Alert Exclusive

EU approves HER2+ Metastatic Breast Cancer Treatment

FDA Approves Companion Diagnostic for Patients with Breast Cancer, Low HER2 Expression 1:36 MD /Alert Exclusive

FDA Approves Companion Diagnostic for Patients with Breast Cancer, Low HER2 Expression

Combination Therapy Fails to Meet Primary Endpoints in HR+ HER2- Breast Cancer Treatment 4:05 MD /Alert Exclusive

Combination Therapy Fails to Meet Primary Endpoints in HR+ HER2- Breast Cancer Treatment

ASCO Issues Guidelines for Telemedicine in Oncology 2:34 MD /Alert Exclusive

ASCO Issues Guidelines for Telemedicine in Oncology

New ASCO, ASTRO, SSO Joint Clinical Guidelines for Hereditary Breast Cancer 4:17 MD /Alert Exclusive

New ASCO, ASTRO, SSO Joint Clinical Guidelines for Hereditary Breast Cancer

Adjuvant Olaparib Significantly Improves Invasive DFS in Patients with High-Risk EBC, BRCA Mutations 3:28 MD /Alert Exclusive

Adjuvant Olaparib Significantly Improves Invasive DFS in Patients with High-Risk EBC, BRCA Mutations

ASCO Updates Guidelines for Patients with HER2+ Breast Cancer and Brain Metastasis 3:29 MD /Alert Exclusive

ASCO Updates Guidelines for Patients with HER2+ Breast Cancer and Brain Metastasis

No OS Benefit with Margetuximab Over Trastuzumab in Previously Treated HER2+ Breast Cancer 2:40 MD /Alert Exclusive

No OS Benefit with Margetuximab Over Trastuzumab in Previously Treated HER2+ Breast Cancer

Oral Paclitaxel-Encequidar Superior to IV Paclitaxel in Metastatic Breast Cancer 2:47 MD /Alert Exclusive

Oral Paclitaxel-Encequidar Superior to IV Paclitaxel in Metastatic Breast Cancer

ASCO Updates Guidelines for Systemic Therapy in Advanced HER2+ Breast Cancer 2:46 MD /Alert Exclusive

ASCO Updates Guidelines for Systemic Therapy in Advanced HER2+ Breast Cancer

Why Dual Light Therapy Hits Triple Negative Breast Cancer Harder 1:37 University of Delaware

Why Dual Light Therapy Hits Triple Negative Breast Cancer Harder

Abemaciclib Represents ‘New Standard of Care’ for Patients With High-Risk Early Breast Cancer 3:26 MD /Alert Exclusive

Abemaciclib Represents ‘New Standard of Care’ for Patients With High-Risk Early Breast Cancer

FDA Issues Warning Alert for Atezolizumab/Paclitaxel Combo in TNBC 1:58 MD /Alert Exclusive

FDA Issues Warning Alert for Atezolizumab/Paclitaxel Combo in TNBC

Capivasertib, Fulvestrant Improves PFS in Patients with HR+/HER2– Breast Cancer 2:46 MD /Alert Exclusive

Capivasertib, Fulvestrant Improves PFS in Patients with HR+/HER2– Breast Cancer

ASCO Guideline on Adjuvant Olaparib in Patients with HER2-negative Breast Cancer 3:39 MD /Alert Exclusive

ASCO Guideline on Adjuvant Olaparib in Patients with HER2-negative Breast Cancer

Metformin Does Not Improve Disease-Free Survival in Early-Stage Breast Cancer Patients 3:48 MD /Alert Exclusive

Metformin Does Not Improve Disease-Free Survival in Early-Stage Breast Cancer Patients

Ribociclib Plus Letrozole Shows Overall Survival Benefit in HR+/HER2- Advanced Breast Cancer 2:17 MD /Alert Exclusive

Ribociclib Plus Letrozole Shows Overall Survival Benefit in HR+/HER2- Advanced Breast Cancer

FDA Approval in BRCA Mutated HER2-negative High-Risk Early Breast Cancer 1:19 MD /Alert Exclusive

FDA Approval in BRCA Mutated HER2-negative High-Risk Early Breast Cancer

Atezolizumab Withdrawn from FDA Accelerated Approval for TNBC 2:17 MD /Alert Exclusive

Atezolizumab Withdrawn from FDA Accelerated Approval for TNBC

Trastuzumab Deruxtecan Improves Survival in HER2-Positive Breast Cancer 2:02 MD /Alert Exclusive

Trastuzumab Deruxtecan Improves Survival in HER2-Positive Breast Cancer

New Uses for Existing Therapies in Breast Cancer Research 2:16 Bellvitge Biomedical Research Institute

New Uses for Existing Therapies in Breast Cancer Research

FDA Grants Fast Track Designation in HR+/HER2- Metastatic Breast Cancer 1:31 MD /Alert Exclusive

FDA Grants Fast Track Designation in HR+/HER2- Metastatic Breast Cancer

Research Shows Benefits of Pembrolizumab as Single Agent TNBC Treatment 2:17 MD /Alert Exclusive

Research Shows Benefits of Pembrolizumab as Single Agent TNBC Treatment

FDA Approves Sacituzumab Govitecan-hziy for Metastatic TNBC 2:15 MD /Alert Exclusive

FDA Approves Sacituzumab Govitecan-hziy for Metastatic TNBC

FDA Approves AI Algorithms for Breast Cancer Detection 1:20 MD /Alert Exclusive

FDA Approves AI Algorithms for Breast Cancer Detection

Pembrolizumab + Chemotherapy Beneficial in Triple-Negative Breast Cancer 3:48 MD /Alert Exclusive

Pembrolizumab + Chemotherapy Beneficial in Triple-Negative Breast Cancer

Clinical Trials Need Better Representation Among Black Patients 2:31 MD /Alert Exclusive

Clinical Trials Need Better Representation Among Black Patients

Various Breast Cancer Research Challenges in Recurrence, Triple Negative BC 1:41 National Cancer Institute

Various Breast Cancer Research Challenges in Recurrence, Triple Negative BC

The Metastatic Spread of Breast Cancer Accelerates During Sleep 2:34 MD /Alert Exclusive

The Metastatic Spread of Breast Cancer Accelerates During Sleep

Chemotherapy Plus Treatment Combination for ERBB2-positive MBC Inferior in Clinical Practice 2:53 MD /Alert Exclusive

Chemotherapy Plus Treatment Combination for ERBB2-positive MBC Inferior in Clinical Practice

Advancing Breast Cancer Care With Gammapod Radiation 1:41 UT Southwestern Medical Center

Advancing Breast Cancer Care With Gammapod Radiation

HER2CLIMB Study Shows Benefits of Triple Therapy for HER2+ Metastatic Breast Cancer with Brain Metastases 2:42 MD /Alert Exclusive

HER2CLIMB Study Shows Benefits of Triple Therapy for HER2+ Metastatic Breast Cancer with Brain Metastases

FDA Approves Trastuzumab Deruxtecan for HER2-Low Breast Cancer 1:13 MD /Alert Exclusive

FDA Approves Trastuzumab Deruxtecan for HER2-Low Breast Cancer

European Regulators Validate TNBC Biologic Treatment Application 1:58 MD /Alert Exclusive

European Regulators Validate TNBC Biologic Treatment Application

New Vaccine to Prevent Breast Cancer in Early Clinical Trials 2:40 MD /Alert Exclusive

New Vaccine to Prevent Breast Cancer in Early Clinical Trials

Providing Equitable Care in Early Breast Cancer 6:11 Medscape

Providing Equitable Care in Early Breast Cancer

Nobel Prize Winner Links Cancer Immunotherapy to Programmed Cell Death Gene 3:45 MD /Alert Exclusive

Nobel Prize Winner Links Cancer Immunotherapy to Programmed Cell Death Gene

Genomic Profiling Improves Metastatic Breast Cancer Research 21:38 Dana Farber

Genomic Profiling Improves Metastatic Breast Cancer Research

Endocrine Therapy Noninferior to Chemotherapy as First-Line Treatment for Patients with MBC 2:05 MD /Alert Exclusive

Endocrine Therapy Noninferior to Chemotherapy as First-Line Treatment for Patients with MBC

Celecoxib Shows No Benefit for Patients with Early Breast Cancer 2:36 MD /Alert Exclusive

Celecoxib Shows No Benefit for Patients with Early Breast Cancer

Sacituzumab Govitecan Safe and Effective in Patients 65 and Older with TNBC 4:37 MD /Alert Exclusive

Sacituzumab Govitecan Safe and Effective in Patients 65 and Older with TNBC

Sacituzumab Govitecan Extends Survival in Metastatic Triple-Negative Breast Cancer 1:58 MD /Alert Exclusive

Sacituzumab Govitecan Extends Survival in Metastatic Triple-Negative Breast Cancer

Understanding Recent Breast Cancer Vaccine Breakthroughs 1:51 WVU Medicine

Understanding Recent Breast Cancer Vaccine Breakthroughs

ASCO Updates Guidelines for Pembrolizumab Treatment in Patients with Early-Stage TNBC 2:44 MD /Alert Exclusive

ASCO Updates Guidelines for Pembrolizumab Treatment in Patients with Early-Stage TNBC

Integrating Tailored Therapy in Early, High-Risk Breast Cancer 5:37 Medscape

Integrating Tailored Therapy in Early, High-Risk Breast Cancer

Some Patients with Invasive Breast Cancer Can Skip Surgery 3:04 MD /Alert Exclusive

Some Patients with Invasive Breast Cancer Can Skip Surgery

Oncologist Explains How Gammapod Works for Breast Cancer 0:55 University of Maryland Medical Center

Oncologist Explains How Gammapod Works for Breast Cancer

FDA Grants Fast Track Designation to Novel Treatment in Breast Cancer 1:29 MD /Alert Exclusive

FDA Grants Fast Track Designation to Novel Treatment in Breast Cancer

MINDACT Study Shows Continued Success in Determining Chemotherapy Usage 3:33 MD /Alert Exclusive

MINDACT Study Shows Continued Success in Determining Chemotherapy Usage

Plasmid DNA Vaccine Shows Promise in Patients with Advanced-Stage ERBB2+ Breast Cancer 3:34 MD /Alert Exclusive

Plasmid DNA Vaccine Shows Promise in Patients with Advanced-Stage ERBB2+ Breast Cancer

RNA TROJAN Promotes Triple-Negative Breast Cancer Progression 2:33 University of Shanghai Cancer Center

RNA TROJAN Promotes Triple-Negative Breast Cancer Progression

FDA Approves Diagnostic to Identify Microsatellite Instability-High Solid Tumors 1:36 MD /Alert Exclusive

FDA Approves Diagnostic to Identify Microsatellite Instability-High Solid Tumors

Atezolizumab Does Not Improve Pathologic Complete Response Rates in HER2+ Early Breast Cancer 3:39 MD /Alert Exclusive

Atezolizumab Does Not Improve Pathologic Complete Response Rates in HER2+ Early Breast Cancer

FDA Grants Bria-IMT Immunotherapy for Metastatic Breast Cancer Fast Track Status 1:46 MD /Alert Exclusive

FDA Grants Bria-IMT Immunotherapy for Metastatic Breast Cancer Fast Track Status

Impassion031 Outcomes Show Importance of Looking Beyond Initial Trial Data 4:39 MD /Alert Exclusive

Impassion031 Outcomes Show Importance of Looking Beyond Initial Trial Data

Pregnancy Does Not Worsen Outcomes in Triple-Negative Breast Cancer 1:39 MD /Alert Exclusive

Pregnancy Does Not Worsen Outcomes in Triple-Negative Breast Cancer

Adjuvant Palbociclib Plus Endocrine Therapy Does Not Improve Outcomes in Patients with Breast Cancer 3:06 MD /Alert Exclusive

Adjuvant Palbociclib Plus Endocrine Therapy Does Not Improve Outcomes in Patients with Breast Cancer

FDA Clears First Clinical Trial for Breast Cancer Vaccine 1:25 MD /Alert Exclusive

FDA Clears First Clinical Trial for Breast Cancer Vaccine

FDA Rejects Breast Cancer Therapy Due to Safety Concerns 1:29 MD /Alert Exclusive

FDA Rejects Breast Cancer Therapy Due to Safety Concerns

Neratinib and Capecitabine Improves PFS in HER2+ Metastatic Breast Cancer 2:00 MD /Alert Exclusive

Neratinib and Capecitabine Improves PFS in HER2+ Metastatic Breast Cancer

Treatment Combination Reduces Recurrence in Early-Stage Breast Cancer 2:29 MD /Alert Exclusive

Treatment Combination Reduces Recurrence in Early-Stage Breast Cancer

Overcoming Treatment Resistance in Breast Cancer 3:58 Brigham and Women's Hospital

Overcoming Treatment Resistance in Breast Cancer

Preventing Breast Cancer in Women Carrying BRCA1 Gene 0:43 Walter and Eliza Hall Institute

Preventing Breast Cancer in Women Carrying BRCA1 Gene

Going the Distance With Metastatic Breast Cancer: 'Personal Best' 5:34 Medscape

Going the Distance With Metastatic Breast Cancer: "Personal Best"

Durvalumab Provokes Robust Long-Term Outcomes in Patients with TNBC 2:11 MD /Alert Exclusive

Durvalumab Provokes Robust Long-Term Outcomes in Patients with TNBC

Breast Cancer Clinical Trial Fails to Meet Primary Endpoint 1:51 MD /Alert Exclusive

Breast Cancer Clinical Trial Fails to Meet Primary Endpoint

Perioperative Combination Therapy Identifies Responders in Early HER2+ Breast Cancer 3:52 MD /Alert Exclusive

Perioperative Combination Therapy Identifies Responders in Early HER2+ Breast Cancer

Olaparib Recommended for European Approval for Patients with High-Risk Early Breast Cancer 1:53 MD /Alert Exclusive

Olaparib Recommended for European Approval for Patients with High-Risk Early Breast Cancer

Researchers Identify Target of Metastasis in Triple-Negative Breast Cancer 2:21 MD /Alert Exclusive

Researchers Identify Target of Metastasis in Triple-Negative Breast Cancer

Neratinib + Capecitabine Improves QoL for HER2+ Metastatic Breast Cancer 3:57 MD /Alert Exclusive

Neratinib + Capecitabine Improves QoL for HER2+ Metastatic Breast Cancer

Studies Emphasizes Need for Universal Testing in Breast Cancer Treatment 2:03 MD /Alert Exclusive

Studies Emphasizes Need for Universal Testing in Breast Cancer Treatment

Trastuzumab Deruxtecan Lowers Risk of Progression in HER2+ Breast Cancer 2:46

Trastuzumab Deruxtecan Lowers Risk of Progression in HER2+ Breast Cancer

SABCS 2023 Annual Meeting

Less Frequent Mammography for Breast Cancer Survivors Has No Impact on Survival 2:42 MD /Alert Exclusive

Less Frequent Mammography for Breast Cancer Survivors Has No Impact on Survival

Fertility Preservation Safe for Patients Who Pause HR-positive Breast Cancer Endocrine Therapy to Conceive 2:46 MD /Alert Exclusive

Fertility Preservation Safe for Patients Who Pause HR-positive Breast Cancer Endocrine Therapy to Conceive

Patients with Breast Cancer That Converts from Lymph Node-Positive to -Negative Can Skip Adjuvant Irradiation 2:30 MD /Alert Exclusive

Patients with Breast Cancer That Converts from Lymph Node-Positive to -Negative Can Skip Adjuvant Irradiation

Tucatinib Plus Trastuzumab Emtansine Extend PFS in Late-Stage HER2-Positive Breast Cancer 2:42 MD /Alert Exclusive

Tucatinib Plus Trastuzumab Emtansine Extend PFS in Late-Stage HER2-Positive Breast Cancer

Younger Postmenopausal Patients May Skip Adjuvant Radiotherapy After Early Breast Cancer Surgery 2:50 MD /Alert Exclusive

Younger Postmenopausal Patients May Skip Adjuvant Radiotherapy After Early Breast Cancer Surgery

MD /Alert Exclusives

ASCO, SSO Publish Guidelines for Germline Mutation Testing in Breast Cancer MD /Alert Exclusive

ASCO, SSO Publish Guidelines for Germline Mutation Testing in Breast Cancer

Less Frequent Mammography for Breast Cancer Survivors Has No Impact on Survival 2:42 MD /Alert Exclusive

Less Frequent Mammography for Breast Cancer Survivors Has No Impact on Survival

Fertility Preservation Safe for Patients Who Pause HR-positive Breast Cancer Endocrine Therapy to Conceive 2:46 MD /Alert Exclusive

Fertility Preservation Safe for Patients Who Pause HR-positive Breast Cancer Endocrine Therapy to Conceive

Patients with Breast Cancer That Converts from Lymph Node-Positive to -Negative Can Skip Adjuvant Irradiation 2:30 MD /Alert Exclusive

Patients with Breast Cancer That Converts from Lymph Node-Positive to -Negative Can Skip Adjuvant Irradiation

Tucatinib Plus Trastuzumab Emtansine Extend PFS in Late-Stage HER2-Positive Breast Cancer 2:42 MD /Alert Exclusive

Tucatinib Plus Trastuzumab Emtansine Extend PFS in Late-Stage HER2-Positive Breast Cancer

Younger Postmenopausal Patients May Skip Adjuvant Radiotherapy After Early Breast Cancer Surgery 2:50 MD /Alert Exclusive

Younger Postmenopausal Patients May Skip Adjuvant Radiotherapy After Early Breast Cancer Surgery

Sacituzumab Govitecan Improves OS in Endocrine-Resistant Metastatic Breast Cancer 2:50 MD /Alert Exclusive

Sacituzumab Govitecan Improves OS in Endocrine-Resistant Metastatic Breast Cancer

Pertuzumab, Trastuzumab Combination Effective in HER2+ Metastatic Breast Cancer 3:20 MD /Alert Exclusive

Pertuzumab, Trastuzumab Combination Effective in HER2+ Metastatic Breast Cancer

PET-CT Scanning Improves Detection of Metastases in Patients With Locally Advanced Breast Cancer 3:21 MD /Alert Exclusive

PET-CT Scanning Improves Detection of Metastases in Patients With Locally Advanced Breast Cancer

NCCN Clinical Practice Guidelines Recommend FES PET Imaging for ER+ Breast Cancer 2:10 MD /Alert Exclusive

NCCN Clinical Practice Guidelines Recommend FES PET Imaging for ER+ Breast Cancer

Camizestrant Improves PFS in Patients with HR+/HER2– Breast Cancer 3:56 MD /Alert Exclusive

Camizestrant Improves PFS in Patients with HR+/HER2– Breast Cancer

Some Patients with Invasive Breast Cancer Can Skip Surgery 3:04 MD /Alert Exclusive

Some Patients with Invasive Breast Cancer Can Skip Surgery

No OS Benefit with Margetuximab Over Trastuzumab in Previously Treated HER2+ Breast Cancer 2:40 MD /Alert Exclusive

No OS Benefit with Margetuximab Over Trastuzumab in Previously Treated HER2+ Breast Cancer

Plasmid DNA Vaccine Shows Promise in Patients with Advanced-Stage ERBB2+ Breast Cancer 3:34 MD /Alert Exclusive

Plasmid DNA Vaccine Shows Promise in Patients with Advanced-Stage ERBB2+ Breast Cancer

Trastuzumab Deruxtecan Significantly Improves OS, PFS in Patients with MBC 2:39 MD /Alert Exclusive

Trastuzumab Deruxtecan Significantly Improves OS, PFS in Patients with MBC

Ribociclib, Endocrine Therapy Combination Improves PFS in Aggressive Breast Cancer 3:16 MD /Alert Exclusive

Ribociclib, Endocrine Therapy Combination Improves PFS in Aggressive Breast Cancer

Inflammatory Markers May Predict Frailty After Chemotherapy 3:09 MD /Alert Exclusive

Inflammatory Markers May Predict Frailty After Chemotherapy

Oral Paclitaxel-Encequidar Superior to IV Paclitaxel in Metastatic Breast Cancer 2:47 MD /Alert Exclusive

Oral Paclitaxel-Encequidar Superior to IV Paclitaxel in Metastatic Breast Cancer

FDA Gives Priority Review for HR+, HER2– Advanced Breast Cancer Therapy 1:45 MD /Alert Exclusive

FDA Gives Priority Review for HR+, HER2– Advanced Breast Cancer Therapy

FDA Approves Companion Diagnostic for Patients with Breast Cancer, Low HER2 Expression 1:36 MD /Alert Exclusive

FDA Approves Companion Diagnostic for Patients with Breast Cancer, Low HER2 Expression

New Test May Detect Multiple Cancers, Tumor Points of Origin 3:02 MD /Alert Exclusive

New Test May Detect Multiple Cancers, Tumor Points of Origin

20-Year Benefit from Endocrine Therapy in Premenopausal Patients with Breast Cancer 2:43 MD /Alert Exclusive

20-Year Benefit from Endocrine Therapy in Premenopausal Patients with Breast Cancer

Atezolizumab Does Not Improve Pathologic Complete Response Rates in HER2+ Early Breast Cancer 3:39 MD /Alert Exclusive

Atezolizumab Does Not Improve Pathologic Complete Response Rates in HER2+ Early Breast Cancer

The Metastatic Spread of Breast Cancer Accelerates During Sleep 2:34 MD /Alert Exclusive

The Metastatic Spread of Breast Cancer Accelerates During Sleep

NCCN Report Advises on Use of Pembrolizumab in Triple-Negative Breast Cancer 2:48 MD /Alert Exclusive

NCCN Report Advises on Use of Pembrolizumab in Triple-Negative Breast Cancer

Pertuzumab-Based Regimen Continues to Reduce Recurrence in Patients with Early Breast Cancer 2:44 MD /Alert Exclusive

Pertuzumab-Based Regimen Continues to Reduce Recurrence in Patients with Early Breast Cancer

FDA Approves Trastuzumab Deruxtecan for HER2-Low Breast Cancer 1:13 MD /Alert Exclusive

FDA Approves Trastuzumab Deruxtecan for HER2-Low Breast Cancer

ICI-Related Major Adverse Cardiac Events Rare, but Cause Significant Morbidity 3:38 MD /Alert Exclusive

ICI-Related Major Adverse Cardiac Events Rare, but Cause Significant Morbidity

Olaparib Recommended for European Approval for Patients with High-Risk Early Breast Cancer 1:53 MD /Alert Exclusive

Olaparib Recommended for European Approval for Patients with High-Risk Early Breast Cancer

European Commission Approves Trastuzumab Deruxtecan for Second-Line HER2+ Breast Cancer 1:53 MD /Alert Exclusive

European Commission Approves Trastuzumab Deruxtecan for Second-Line HER2+ Breast Cancer

ASCO Updates Guidelines for Patients with HER2+ Breast Cancer and Brain Metastasis 3:29 MD /Alert Exclusive

ASCO Updates Guidelines for Patients with HER2+ Breast Cancer and Brain Metastasis

Neoadjuvant Amcenestrant Shows Robust Response in Postmenopausal ER+/HER2- Breast Cancer 2:29 MD /Alert Exclusive

Neoadjuvant Amcenestrant Shows Robust Response in Postmenopausal ER+/HER2- Breast Cancer

ASCO Updates Guidelines for Systemic Therapy in Advanced HER2+ Breast Cancer 2:46 MD /Alert Exclusive

ASCO Updates Guidelines for Systemic Therapy in Advanced HER2+ Breast Cancer

Treatment Combination Shows Promise in HR+, HER2–, HER2-mutant Metastatic Breast Cancer 3:18 MD /Alert Exclusive

Treatment Combination Shows Promise in HR+, HER2–, HER2-mutant Metastatic Breast Cancer

Zanidatamab-Docetaxel Effective as First-Line Therapy in Advanced HER2+ Breast Cancer 3:28 MD /Alert Exclusive

Zanidatamab-Docetaxel Effective as First-Line Therapy in Advanced HER2+ Breast Cancer

Perioperative Combination Therapy Identifies Responders in Early HER2+ Breast Cancer 3:52 MD /Alert Exclusive

Perioperative Combination Therapy Identifies Responders in Early HER2+ Breast Cancer

FDA Approves Biosimilar Treatment for Cancer-Related Neutropenia 1:03 MD /Alert Exclusive

FDA Approves Biosimilar Treatment for Cancer-Related Neutropenia

Metformin Does Not Improve Disease-Free Survival in Early-Stage Breast Cancer Patients 3:48 MD /Alert Exclusive

Metformin Does Not Improve Disease-Free Survival in Early-Stage Breast Cancer Patients

Sacituzumab Govitecan Safe and Effective in Patients 65 and Older with TNBC 4:37 MD /Alert Exclusive

Sacituzumab Govitecan Safe and Effective in Patients 65 and Older with TNBC

FDA Approves AI Algorithms for Breast Cancer Detection 1:20 MD /Alert Exclusive

FDA Approves AI Algorithms for Breast Cancer Detection

Palbociclib Combination Fails to Extend Overall Survival for Advanced Breast Cancer 2:35 MD /Alert Exclusive

Palbociclib Combination Fails to Extend Overall Survival for Advanced Breast Cancer

Protein Coding Gene Enhances Cisplatin Resistance in Triple-Negative Breast Cancer 2:45 MD /Alert Exclusive

Protein Coding Gene Enhances Cisplatin Resistance in Triple-Negative Breast Cancer

Trastuzumab Deruxtecan Highly Effective in Patients with HER2-Low Metastatic Breast Cancer 2:53 MD /Alert Exclusive

Trastuzumab Deruxtecan Highly Effective in Patients with HER2-Low Metastatic Breast Cancer

Clinical Trials Need Better Representation Among Black Patients 2:31 MD /Alert Exclusive

Clinical Trials Need Better Representation Among Black Patients

FDA Grants Bria-IMT Immunotherapy for Metastatic Breast Cancer Fast Track Status 1:46 MD /Alert Exclusive

FDA Grants Bria-IMT Immunotherapy for Metastatic Breast Cancer Fast Track Status

Adjuvant Palbociclib Plus Endocrine Therapy Does Not Improve Outcomes in Patients with Breast Cancer 3:06 MD /Alert Exclusive

Adjuvant Palbociclib Plus Endocrine Therapy Does Not Improve Outcomes in Patients with Breast Cancer

Lumpectomy, Mastectomy Result in Similar Outcomes in Younger Patients with Breast Cancer 2:22 MD /Alert Exclusive

Lumpectomy, Mastectomy Result in Similar Outcomes in Younger Patients with Breast Cancer

ASCO Updates Guidelines for Pembrolizumab Treatment in Patients with Early-Stage TNBC 2:44 MD /Alert Exclusive

ASCO Updates Guidelines for Pembrolizumab Treatment in Patients with Early-Stage TNBC

Results from BEATRICE and I–SPY2 Trials in TNBC and HR+/HER2- Breast Cancer 2:14 MD /Alert Exclusive

Results from BEATRICE and I–SPY2 Trials in TNBC and HR+/HER2- Breast Cancer

No Benefit with Early Local Therapy In De Novo Metastatic Breast Cancer 2:34 MD /Alert Exclusive

No Benefit with Early Local Therapy In De Novo Metastatic Breast Cancer

Ribociclib Plus Letrozole Shows Overall Survival Benefit in HR+/HER2- Advanced Breast Cancer 2:17 MD /Alert Exclusive

Ribociclib Plus Letrozole Shows Overall Survival Benefit in HR+/HER2- Advanced Breast Cancer

Trastuzumab Deruxtecan Lowers Risk of Progression in HER2+ Breast Cancer 2:46

Trastuzumab Deruxtecan Lowers Risk of Progression in HER2+ Breast Cancer

Trastuzumab Deruxtecan Lowers Risk of Progression in HER2+ Breast Cancer 2:46 MD /Alert Exclusive

Trastuzumab Deruxtecan Lowers Risk of Progression in HER2+ Breast Cancer

Breast Cancer Clinical Trial Fails to Meet Primary Endpoint 1:51 MD /Alert Exclusive

Breast Cancer Clinical Trial Fails to Meet Primary Endpoint

Olaparib Improves Survival in High Risk Early-Stage Breast Cancer 1:44 MD /Alert Exclusive

Olaparib Improves Survival in High Risk Early-Stage Breast Cancer

FDA Grants Fast Track Designation to Novel Treatment in Breast Cancer 1:29 MD /Alert Exclusive

FDA Grants Fast Track Designation to Novel Treatment in Breast Cancer

Researchers Identify Target of Metastasis in Triple-Negative Breast Cancer 2:21 MD /Alert Exclusive

Researchers Identify Target of Metastasis in Triple-Negative Breast Cancer

FDA Approval in BRCA Mutated HER2-negative High-Risk Early Breast Cancer 1:19 MD /Alert Exclusive

FDA Approval in BRCA Mutated HER2-negative High-Risk Early Breast Cancer

Treatment Combination Reduces Recurrence in Early-Stage Breast Cancer 2:29 MD /Alert Exclusive

Treatment Combination Reduces Recurrence in Early-Stage Breast Cancer

ASCO Issues Guidelines for Telemedicine in Oncology 2:34 MD /Alert Exclusive

ASCO Issues Guidelines for Telemedicine in Oncology

FDA Approves Diagnostic to Identify Microsatellite Instability-High Solid Tumors 1:36 MD /Alert Exclusive

FDA Approves Diagnostic to Identify Microsatellite Instability-High Solid Tumors

Pregnancy Does Not Worsen Outcomes in Triple-Negative Breast Cancer 1:39 MD /Alert Exclusive

Pregnancy Does Not Worsen Outcomes in Triple-Negative Breast Cancer

Metastatic Breast Cancer Therapy Gains Fast Track Designation 1:25 MD /Alert Exclusive

Metastatic Breast Cancer Therapy Gains Fast Track Designation

Nitric Oxide Synthase Inhibitor Plus Taxane Show Promise in Chemoresistant TNBC 4:30 MD /Alert Exclusive

Nitric Oxide Synthase Inhibitor Plus Taxane Show Promise in Chemoresistant TNBC

FDA Accepts Biologics License Application for New Metastatic HER2+ Breast Cancer Treatment 2:06 MD /Alert Exclusive

FDA Accepts Biologics License Application for New Metastatic HER2+ Breast Cancer Treatment

FDA Grants Fast Track Designation in HR+/HER2- Metastatic Breast Cancer 1:31 MD /Alert Exclusive

FDA Grants Fast Track Designation in HR+/HER2- Metastatic Breast Cancer

New Vaccine to Prevent Breast Cancer in Early Clinical Trials 2:40 MD /Alert Exclusive

New Vaccine to Prevent Breast Cancer in Early Clinical Trials

Therapy Targeting Inducible Nitric Oxide Signaling Shows Promise in TNBC 4:37 MD /Alert Exclusive

Therapy Targeting Inducible Nitric Oxide Signaling Shows Promise in TNBC

Trastuzumab Deruxtecan Improves Survival in HER2-Positive Breast Cancer 2:02 MD /Alert Exclusive

Trastuzumab Deruxtecan Improves Survival in HER2-Positive Breast Cancer

FDA Approves Combo of Abemaciclib, Endocrine Therapy for Early Breast Cancer 1:51 MD /Alert Exclusive

FDA Approves Combo of Abemaciclib, Endocrine Therapy for Early Breast Cancer

Atezolizumab Withdrawn from FDA Accelerated Approval for TNBC 2:17 MD /Alert Exclusive

Atezolizumab Withdrawn from FDA Accelerated Approval for TNBC

Celecoxib Shows No Benefit for Patients with Early Breast Cancer 2:36 MD /Alert Exclusive

Celecoxib Shows No Benefit for Patients with Early Breast Cancer

Research Shows Benefits of Pembrolizumab as Single Agent TNBC Treatment 2:17 MD /Alert Exclusive

Research Shows Benefits of Pembrolizumab as Single Agent TNBC Treatment

Chemotherapy Plus Treatment Combination for ERBB2-positive MBC Inferior in Clinical Practice 2:53 MD /Alert Exclusive

Chemotherapy Plus Treatment Combination for ERBB2-positive MBC Inferior in Clinical Practice

ASCO Guideline on Adjuvant Olaparib in Patients with HER2-negative Breast Cancer 3:39 MD /Alert Exclusive

ASCO Guideline on Adjuvant Olaparib in Patients with HER2-negative Breast Cancer

Durvalumab Provokes Robust Long-Term Outcomes in Patients with TNBC 2:11 MD /Alert Exclusive

Durvalumab Provokes Robust Long-Term Outcomes in Patients with TNBC

Endocrine Therapy Noninferior to Chemotherapy as First-Line Treatment for Patients with MBC 2:05 MD /Alert Exclusive

Endocrine Therapy Noninferior to Chemotherapy as First-Line Treatment for Patients with MBC

Adjuvant Olaparib Significantly Improves Invasive DFS in Patients with High-Risk EBC, BRCA Mutations 3:28 MD /Alert Exclusive

Adjuvant Olaparib Significantly Improves Invasive DFS in Patients with High-Risk EBC, BRCA Mutations

FDA Approves Sacituzumab Govitecan-hziy for Metastatic TNBC 2:15 MD /Alert Exclusive

FDA Approves Sacituzumab Govitecan-hziy for Metastatic TNBC

European Regulators Validate TNBC Biologic Treatment Application 1:58 MD /Alert Exclusive

European Regulators Validate TNBC Biologic Treatment Application

FDA Rejects Breast Cancer Therapy Due to Safety Concerns 1:29 MD /Alert Exclusive

FDA Rejects Breast Cancer Therapy Due to Safety Concerns

Large Epidemiology Study Updates Breast Cancer Risk for Women Lacking Family History 1:51 MD /Alert Exclusive

Large Epidemiology Study Updates Breast Cancer Risk for Women Lacking Family History

FDA Committee Delays Approval of Pembrolizumab for Early TNBC 2:25 MD /Alert Exclusive

FDA Committee Delays Approval of Pembrolizumab for Early TNBC

FDA Clears First Clinical Trial for Breast Cancer Vaccine 1:25 MD /Alert Exclusive

FDA Clears First Clinical Trial for Breast Cancer Vaccine

Helping Breast Cancer Oncologists Work ‘In the Trenches’ 4:43 MD /Alert Exclusive

Helping Breast Cancer Oncologists Work ‘In the Trenches’

New ASCO, ASTRO, SSO Joint Clinical Guidelines for Hereditary Breast Cancer 4:17 MD /Alert Exclusive

New ASCO, ASTRO, SSO Joint Clinical Guidelines for Hereditary Breast Cancer

EU approves HER2+ Metastatic Breast Cancer Treatment 2:31 MD /Alert Exclusive

EU approves HER2+ Metastatic Breast Cancer Treatment

Studies Emphasizes Need for Universal Testing in Breast Cancer Treatment 2:03 MD /Alert Exclusive

Studies Emphasizes Need for Universal Testing in Breast Cancer Treatment

Impassion031 Outcomes Show Importance of Looking Beyond Initial Trial Data 4:39 MD /Alert Exclusive

Impassion031 Outcomes Show Importance of Looking Beyond Initial Trial Data

Combination Therapy Fails to Meet Primary Endpoints in HR+ HER2- Breast Cancer Treatment 4:05 MD /Alert Exclusive

Combination Therapy Fails to Meet Primary Endpoints in HR+ HER2- Breast Cancer Treatment

Mindfulness Shows Benefits for Young Breast Cancer 4:40 MD /Alert Exclusive

Mindfulness Shows Benefits for Young Breast Cancer

Time to Treatment Completion Associated with Poor Breast Cancer Survival 3:18 MD /Alert Exclusive

Time to Treatment Completion Associated with Poor Breast Cancer Survival

Neratinib + Capecitabine Improves QoL for HER2+ Metastatic Breast Cancer 3:57 MD /Alert Exclusive

Neratinib + Capecitabine Improves QoL for HER2+ Metastatic Breast Cancer

Study Shows Breastfeeding Can be Safe for Breast Cancer Survivors 4:08 MD /Alert Exclusive

Study Shows Breastfeeding Can be Safe for Breast Cancer Survivors

Abemaciclib Represents ‘New Standard of Care’ for Patients With High-Risk Early Breast Cancer 3:26 MD /Alert Exclusive

Abemaciclib Represents ‘New Standard of Care’ for Patients With High-Risk Early Breast Cancer

Sacituzumab Govitecan Extends Survival in Metastatic Triple-Negative Breast Cancer 1:58 MD /Alert Exclusive

Sacituzumab Govitecan Extends Survival in Metastatic Triple-Negative Breast Cancer

FDA Issues Warning Alert for Atezolizumab/Paclitaxel Combo in TNBC 1:58 MD /Alert Exclusive

FDA Issues Warning Alert for Atezolizumab/Paclitaxel Combo in TNBC

Nobel Prize Winner Links Cancer Immunotherapy to Programmed Cell Death Gene 3:45 MD /Alert Exclusive

Nobel Prize Winner Links Cancer Immunotherapy to Programmed Cell Death Gene

Neratinib and Capecitabine Improves PFS in HER2+ Metastatic Breast Cancer 2:00 MD /Alert Exclusive

Neratinib and Capecitabine Improves PFS in HER2+ Metastatic Breast Cancer

MINDACT Study Shows Continued Success in Determining Chemotherapy Usage 3:33 MD /Alert Exclusive

MINDACT Study Shows Continued Success in Determining Chemotherapy Usage

Pembrolizumab + Chemotherapy Beneficial in Triple-Negative Breast Cancer 3:48 MD /Alert Exclusive

Pembrolizumab + Chemotherapy Beneficial in Triple-Negative Breast Cancer

Advanced ER+ HER2+ Breast Cancer Combo Therapy Fails to Improve Outcomes 3:30 MD /Alert Exclusive

Advanced ER+ HER2+ Breast Cancer Combo Therapy Fails to Improve Outcomes

HER2CLIMB Study Shows Benefits of Triple Therapy for HER2+ Metastatic Breast Cancer with Brain Metastases 2:42 MD /Alert Exclusive

HER2CLIMB Study Shows Benefits of Triple Therapy for HER2+ Metastatic Breast Cancer with Brain Metastases

Featured Breast Cancer Videos

Breaking Research

Personalized Assay Surpasses Limits for Detecting Tumor DNA in Breast Cancer Patients 5:16 Translational Genomics Research Institute

Personalized Assay Surpasses Limits for Detecting Tumor DNA in Breast Cancer Patients

Overcoming Treatment Resistance in Breast Cancer 3:58 Brigham and Women's Hospital

Overcoming Treatment Resistance in Breast Cancer

Oncologist Explains How Gammapod Works for Breast Cancer 0:55 University of Maryland Medical Center

Oncologist Explains How Gammapod Works for Breast Cancer

Advancing Breast Cancer Care With Gammapod Radiation 1:41 UT Southwestern Medical Center

Advancing Breast Cancer Care With Gammapod Radiation

RNA TROJAN Promotes Triple-Negative Breast Cancer Progression 2:33 University of Shanghai Cancer Center

RNA TROJAN Promotes Triple-Negative Breast Cancer Progression

Preventing Breast Cancer in Women Carrying BRCA1 Gene 0:43 Walter and Eliza Hall Institute

Preventing Breast Cancer in Women Carrying BRCA1 Gene

ASCO 2023 Annual Meeting

Donepezil Does Not Improve Cancer-Related Cognitive Impairment in Breast Cancer Survivors 2:26 LIVE FROM ASCO

Donepezil Does Not Improve Cancer-Related Cognitive Impairment in Breast Cancer Survivors

Breast Cancer Index Risk Scores a Prognostic Indicator of Overall, Late Distant Recurrence 2:20 LIVE FROM ASCO

Breast Cancer Index Risk Scores a Prognostic Indicator of Overall, Late Distant Recurrence

HER3-DXd Promotes Clinical Activity in MBC at Varying HER3 Expression Levels 3:50 LIVE FROM ASCO

HER3-DXd Promotes Clinical Activity in MBC at Varying HER3 Expression Levels

Capecitabine Has Less Toxicity, Similar Survival in Metastatic Breast Cancer with Fixed Dose 2:07 LIVE FROM ASCO

Capecitabine Has Less Toxicity, Similar Survival in Metastatic Breast Cancer with Fixed Dose

Greater Weight Loss Among Women with Breast Cancer After Phone-Based Coaching 2:35 LIVE FROM ASCO

Greater Weight Loss Among Women with Breast Cancer After Phone-Based Coaching

Curated For You

Genomic Profiling Improves Metastatic Breast Cancer Research 21:38 Dana Farber

Genomic Profiling Improves Metastatic Breast Cancer Research

New Uses for Existing Therapies in Breast Cancer Research 2:16 Bellvitge Biomedical Research Institute

New Uses for Existing Therapies in Breast Cancer Research

Various Breast Cancer Research Challenges in Recurrence, Triple Negative BC 1:41 National Cancer Institute

Various Breast Cancer Research Challenges in Recurrence, Triple Negative BC

Understanding Recent Breast Cancer Vaccine Breakthroughs 1:51 WVU Medicine

Understanding Recent Breast Cancer Vaccine Breakthroughs

Study of Immunotherapy Combinations for Patients with Metastatic Breast Cancer 4:26 Dana Farber

Study of Immunotherapy Combinations for Patients with Metastatic Breast Cancer

Why Dual Light Therapy Hits Triple Negative Breast Cancer Harder 1:37 University of Delaware

Why Dual Light Therapy Hits Triple Negative Breast Cancer Harder

Improving Outcomes for Early Onset Breast Cancer 12:17 CDC

Improving Outcomes for Early Onset Breast Cancer

SABCS 2022 Annual Meeting

Capivasertib, Fulvestrant Improves PFS in Patients with HR+/HER2– Breast Cancer 2:46 MD /Alert Exclusive

Capivasertib, Fulvestrant Improves PFS in Patients with HR+/HER2– Breast Cancer

Camizestrant Improves PFS in Patients with HR+/HER2– Breast Cancer 3:56 MD /Alert Exclusive

Camizestrant Improves PFS in Patients with HR+/HER2– Breast Cancer

Trastuzumab Deruxtecan Significantly Improves OS, PFS in Patients with MBC 2:39 MD /Alert Exclusive

Trastuzumab Deruxtecan Significantly Improves OS, PFS in Patients with MBC

Ribociclib, Endocrine Therapy Combination Improves PFS in Aggressive Breast Cancer 3:16 MD /Alert Exclusive

Ribociclib, Endocrine Therapy Combination Improves PFS in Aggressive Breast Cancer

ASCO 2022 Annual Meeting

FDA Approves Trastuzumab Deruxtecan for HER2-Low Breast Cancer 1:13 MD /Alert Exclusive

FDA Approves Trastuzumab Deruxtecan for HER2-Low Breast Cancer

European Commission Approves Trastuzumab Deruxtecan for Second-Line HER2+ Breast Cancer 1:53 MD /Alert Exclusive

European Commission Approves Trastuzumab Deruxtecan for Second-Line HER2+ Breast Cancer

Treatment Combination Shows Promise in HR+, HER2–, HER2-mutant Metastatic Breast Cancer 3:18 MD /Alert Exclusive

Treatment Combination Shows Promise in HR+, HER2–, HER2-mutant Metastatic Breast Cancer

Zanidatamab-Docetaxel Effective as First-Line Therapy in Advanced HER2+ Breast Cancer 3:28 MD /Alert Exclusive

Zanidatamab-Docetaxel Effective as First-Line Therapy in Advanced HER2+ Breast Cancer

Sacituzumab Govitecan Safe and Effective in Patients 65 and Older with TNBC 4:37 MD /Alert Exclusive

Sacituzumab Govitecan Safe and Effective in Patients 65 and Older with TNBC

Palbociclib Combination Fails to Extend Overall Survival for Advanced Breast Cancer 2:35 MD /Alert Exclusive

Palbociclib Combination Fails to Extend Overall Survival for Advanced Breast Cancer

Trastuzumab Deruxtecan Highly Effective in Patients with HER2-Low Metastatic Breast Cancer 2:53 MD /Alert Exclusive

Trastuzumab Deruxtecan Highly Effective in Patients with HER2-Low Metastatic Breast Cancer

Clinical Trials Need Better Representation Among Black Patients 2:31 MD /Alert Exclusive

Clinical Trials Need Better Representation Among Black Patients

SABCS 2020 Annual Meeting

FDA Committee Delays Approval of Pembrolizumab for Early TNBC 2:25 MD /Alert Exclusive

FDA Committee Delays Approval of Pembrolizumab for Early TNBC

FDA Clears First Clinical Trial for Breast Cancer Vaccine 1:25 MD /Alert Exclusive

FDA Clears First Clinical Trial for Breast Cancer Vaccine

Helping Breast Cancer Oncologists Work ‘In the Trenches’ 4:43 MD /Alert Exclusive

Helping Breast Cancer Oncologists Work ‘In the Trenches’

EU approves HER2+ Metastatic Breast Cancer Treatment 2:31 MD /Alert Exclusive

EU approves HER2+ Metastatic Breast Cancer Treatment

Studies Emphasizes Need for Universal Testing in Breast Cancer Treatment 2:03 MD /Alert Exclusive

Studies Emphasizes Need for Universal Testing in Breast Cancer Treatment

Impassion031 Outcomes Show Importance of Looking Beyond Initial Trial Data 4:39 MD /Alert Exclusive

Impassion031 Outcomes Show Importance of Looking Beyond Initial Trial Data

Combination Therapy Fails to Meet Primary Endpoints in HR+ HER2- Breast Cancer Treatment 4:05 MD /Alert Exclusive

Combination Therapy Fails to Meet Primary Endpoints in HR+ HER2- Breast Cancer Treatment

Mindfulness Shows Benefits for Young Breast Cancer 4:40 MD /Alert Exclusive

Mindfulness Shows Benefits for Young Breast Cancer

Time to Treatment Completion Associated with Poor Breast Cancer Survival 3:18 MD /Alert Exclusive

Time to Treatment Completion Associated with Poor Breast Cancer Survival

Neratinib + Capecitabine Improves QoL for HER2+ Metastatic Breast Cancer 3:57 MD /Alert Exclusive

Neratinib + Capecitabine Improves QoL for HER2+ Metastatic Breast Cancer

ASCO 2020 Annual Meeting

MINDACT Study Shows Continued Success in Determining Chemotherapy Usage 3:33 MD /Alert Exclusive

MINDACT Study Shows Continued Success in Determining Chemotherapy Usage

Pembrolizumab + Chemotherapy Beneficial in Triple-Negative Breast Cancer 3:48 MD /Alert Exclusive

Pembrolizumab + Chemotherapy Beneficial in Triple-Negative Breast Cancer

Advanced ER+ HER2+ Breast Cancer Combo Therapy Fails to Improve Outcomes 3:30 MD /Alert Exclusive

Advanced ER+ HER2+ Breast Cancer Combo Therapy Fails to Improve Outcomes

HER2CLIMB Study Shows Benefits of Triple Therapy for HER2+ Metastatic Breast Cancer with Brain Metastases 2:42 MD /Alert Exclusive

HER2CLIMB Study Shows Benefits of Triple Therapy for HER2+ Metastatic Breast Cancer with Brain Metastases

Study Shows Tolerable Safety of Abemaciclib Plus Pembrolizumab in HER2-, Metastatic Breast Cancer 2:21 MD /Alert Exclusive

Study Shows Tolerable Safety of Abemaciclib Plus Pembrolizumab in HER2-, Metastatic Breast Cancer

Combining Eribulin and Pembrolizumab in Metastatic Triple-Negative Breast Cancer 3:09 MD /Alert Exclusive

Combining Eribulin and Pembrolizumab in Metastatic Triple-Negative Breast Cancer